読み込み中
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
前日終値
$168.35
−$1.73 · -1.02%
日中の時刻はETです。市場データは遅延する場合があります。
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
日中レンジ
現在 $168.35
52週レンジ
現在 $168.35
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
66
割安
センチメント
64
強気
リスク
27
中程度のリスク
モメンタム
59
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
日中レンジ
現在 $168.35
52週レンジ
現在 $168.35
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6.38億 USD | 3.86億 USD | 2.71億 USD | 5003.7万 USD | — |
| 売上原価 | 4747.8万 USD | 3330.3万 USD | 2606.5万 USD | 519.8万 USD | — |
| 粗利益 | 5.91億 USD | 3.52億 USD | 2.45億 USD | 4483.9万 USD | — |
| 研究開発 | 1.83億 USD | 1.87億 USD | 9794.4万 USD | 5794.7万 USD | 5806.1万 USD |
| 販売・一般管理 | 5.71億 USD | 4.11億 USD | 3.23億 USD | 1.59億 USD | 6664.6万 USD |
| 営業費用 | 7.6億 USD | 6.33億 USD | 4.76億 USD | 2.25億 USD | 1.25億 USD |
| 受取利息 | 937.1万 USD | — | — | — | — |
| 支払利息 | 655.7万 USD | 656.9万 USD | 645.3万 USD | 733.5万 USD | 569.6万 USD |
| 減価償却費と償却費 | 906.4万 USD | 795.8万 USD | 683.4万 USD | 440.2万 USD | 7.6万 USD |
| 営業利益 | −1.69億 USD | −2.81億 USD | −2.32億 USD | −1.8億 USD | −1.25億 USD |
| 純利益 | −1.83億 USD | −2.87億 USD | −2.39億 USD | −1.87億 USD | −1.3億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$283
上昇余地（68.10%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI2.76億0.01%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB2億0.11%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK1.15億0.25%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF9971.92万0.10%954億 USD0.05%$235+0.80%
First Trust NYSE Arca Biotechnology Index FundFBT6519.2万2.25%28.91億 USD0.55%$265.4+2.00%
iShares Biotechnology ETFIBB5805.1万0.55%108.2億 USD0.44%$206.49+3.00%
iShares Russell Mid-Cap Growth ETFIWP4134.56万0.21%200.95億 USD0.23%$143.1+1.56%
Schwab U.S. Small-Cap ETFSCHA4017.26万0.18%218.24億 USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBiShares Russell Mid-Cap Growth ETFIWPSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
